Cutaneous reactions with enfortumab vedotin: A case series and review of the literature

Abstract

Enfortumab vedotin (EV) is a novel treatment for patients with advanced urothelial carcinoma who have failed platinum-based chemotherapy and immunotherapy.1 EV is an antibody-drug conjugate (ADC) composed of a humanized anti-nectin-4 monoclonal antibody attached to a microtubule inhibitor.2 We report 3 individuals with unique cutaneous reactions after EV treatment.